Simcere Pharmaceutical Group Limited's (HKG:2096) 30% Jump Shows Its Popularity With Investors

Despite an already strong run, Simcere Pharmaceutical Group Limited (HKG:2096) shares have been powering on, with a gain of 30% in the last thirty days. The annual gain comes to 175% following the latest surge, making investors sit up and take notice.

Following the firm bounce in price, Simcere Pharmaceutical Group's price-to-earnings (or "P/E") ratio of 44.1x might make it look like a strong sell right now compared to the market in Hong Kong, where around half of the companies have P/E ratios below 12x and even P/E's below 7x are quite common. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the highly elevated P/E.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

With earnings growth that's superior to most other companies of late, Simcere Pharmaceutical Group has been doing relatively well. It seems that many are expecting the strong earnings performance to persist, which has raised the P/E. You'd really hope so, otherwise you're paying a pretty hefty price for no particular reason.

View our latest analysis for Simcere Pharmaceutical Group

Keen to find out how analysts think Simcere Pharmaceutical Group's future stacks up against the industry? In that case, our free report is a great place to start.

How Is Simcere Pharmaceutical Group's Growth Trending?

The only time you'd be truly comfortable seeing a P/E as steep as Simcere Pharmaceutical Group's is when the company's growth is on track to outshine the market decidedly.

If we review the last year of earnings growth, the company posted a worthy increase of 6.5%. However, this wasn't enough as the latest three year period has seen an unpleasant 49% overall drop in EPS. Therefore, it's fair to say the earnings growth recently has been undesirable for the company.

Looking ahead now, EPS is anticipated to climb by 29% each year during the coming three years according to the five analysts following the company. With the market only predicted to deliver 15% per year, the company is positioned for a stronger earnings result.

With this information, we can see why Simcere Pharmaceutical Group is trading at such a high P/E compared to the market. It seems most investors are expecting this strong future growth and are willing to pay more for the stock.

What We Can Learn From Simcere Pharmaceutical Group's P/E?

The strong share price surge has got Simcere Pharmaceutical Group's P/E rushing to great heights as well. It's argued the price-to-earnings ratio is an inferior measure of value within certain industries, but it can be a powerful business sentiment indicator.

We've established that Simcere Pharmaceutical Group maintains its high P/E on the strength of its forecast growth being higher than the wider market, as expected. At this stage investors feel the potential for a deterioration in earnings isn't great enough to justify a lower P/E ratio. Unless these conditions change, they will continue to provide strong support to the share price.

It's always necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with Simcere Pharmaceutical Group, and understanding should be part of your investment process.

You might be able to find a better investment than Simcere Pharmaceutical Group. If you want a selection of possible candidates, check out this free list of interesting companies that trade on a low P/E (but have proven they can grow earnings).

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.